Cargando…

Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial

Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyttel-Sorensen, Simon, Pellicer, Adelina, Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Franz, Axel R, Fumagalli, Monica, Gluud, Christian, Grevstad, Berit, Hagmann, Cornelia, Lemmers, Petra, van Oeveren, Wim, Pichler, Gerhard, Plomgaard, Anne Mette, Riera, Joan, Sanchez, Laura, Winkel, Per, Wolf, Martin, Greisen, Gorm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283997/
https://www.ncbi.nlm.nih.gov/pubmed/25569128
http://dx.doi.org/10.1136/bmj.g7635
_version_ 1782351354876919808
author Hyttel-Sorensen, Simon
Pellicer, Adelina
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Franz, Axel R
Fumagalli, Monica
Gluud, Christian
Grevstad, Berit
Hagmann, Cornelia
Lemmers, Petra
van Oeveren, Wim
Pichler, Gerhard
Plomgaard, Anne Mette
Riera, Joan
Sanchez, Laura
Winkel, Per
Wolf, Martin
Greisen, Gorm
author_facet Hyttel-Sorensen, Simon
Pellicer, Adelina
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Franz, Axel R
Fumagalli, Monica
Gluud, Christian
Grevstad, Berit
Hagmann, Cornelia
Lemmers, Petra
van Oeveren, Wim
Pichler, Gerhard
Plomgaard, Anne Mette
Riera, Joan
Sanchez, Laura
Winkel, Per
Wolf, Martin
Greisen, Gorm
author_sort Hyttel-Sorensen, Simon
collection PubMed
description Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in eight European countries. Participants 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support. Interventions Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control). Main outcome measures The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography. Randomisation Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥26 weeks). Blinding Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation. Results The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device. Conclusions Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring. Trial registration ClinicalTrial.gov NCT01590316.
format Online
Article
Text
id pubmed-4283997
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-42839972015-01-08 Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial Hyttel-Sorensen, Simon Pellicer, Adelina Alderliesten, Thomas Austin, Topun van Bel, Frank Benders, Manon Claris, Olivier Dempsey, Eugene Franz, Axel R Fumagalli, Monica Gluud, Christian Grevstad, Berit Hagmann, Cornelia Lemmers, Petra van Oeveren, Wim Pichler, Gerhard Plomgaard, Anne Mette Riera, Joan Sanchez, Laura Winkel, Per Wolf, Martin Greisen, Gorm BMJ Research Objective To determine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants monitored by cerebral near infrared spectroscopy (NIRS) oximetry. Design Phase II randomised, single blinded, parallel clinical trial. Setting Eight tertiary neonatal intensive care units in eight European countries. Participants 166 extremely preterm infants born before 28 weeks of gestation: 86 were randomised to cerebral NIRS monitoring and 80 to blinded NIRS monitoring. The only exclusion criterion was a decision not to provide life support. Interventions Monitoring of cerebral oxygenation using NIRS in combination with a dedicated treatment guideline during the first 72 hours of life (experimental) compared with blinded NIRS oxygenation monitoring with standard care (control). Main outcome measures The primary outcome measure was the time spent outside the target range of 55-85% for cerebral oxygenation multiplied by the mean absolute deviation, expressed in %hours (burden of hypoxia and hyperoxia). One hour with an oxygenation of 50% gives 5%hours of hypoxia. Secondary outcomes were all cause mortality at term equivalent age and a brain injury score assessed by cerebral ultrasonography. Randomisation Allocation sequence 1:1 with block sizes 4 and 6 in random order concealed for the investigators. The allocation was stratified for gestational age (<26 weeks or ≥26 weeks). Blinding Cerebral oxygenation measurements were blinded in the control group. All outcome assessors were blinded to group allocation. Results The 86 infants randomised to the NIRS group had a median burden of hypoxia and hyperoxia of 36.1%hours (interquartile range 9.2-79.5%hours) compared with 81.3 (38.5-181.3) %hours in the control group, a reduction of 58% (95% confidence interval 35% to 73%, P<0.001). In the experimental group the median burden of hypoxia was 16.6 (interquartile range 5.4-68.1) %hours, compared with 53.6 (17.4-171.3) %hours in the control group (P=0.0012). The median burden of hyperoxia was similar between the groups: 1.2 (interquartile range 0.3-9.6) %hours in the experimental group compared with 1.1 (0.1-23.4) %hours in the control group (P=0.98). We found no statistically significant differences between the two groups at term corrected age. No severe adverse reactions were associated with the device. Conclusions Cerebral oxygenation was stabilised in extremely preterm infants using a dedicated treatment guideline in combination with cerebral NIRS monitoring. Trial registration ClinicalTrial.gov NCT01590316. BMJ Publishing Group Ltd. 2015-01-05 /pmc/articles/PMC4283997/ /pubmed/25569128 http://dx.doi.org/10.1136/bmj.g7635 Text en © Hyttel-Sorensen et al 2015 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Research
Hyttel-Sorensen, Simon
Pellicer, Adelina
Alderliesten, Thomas
Austin, Topun
van Bel, Frank
Benders, Manon
Claris, Olivier
Dempsey, Eugene
Franz, Axel R
Fumagalli, Monica
Gluud, Christian
Grevstad, Berit
Hagmann, Cornelia
Lemmers, Petra
van Oeveren, Wim
Pichler, Gerhard
Plomgaard, Anne Mette
Riera, Joan
Sanchez, Laura
Winkel, Per
Wolf, Martin
Greisen, Gorm
Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title_full Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title_fullStr Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title_full_unstemmed Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title_short Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial
title_sort cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase ii randomised clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283997/
https://www.ncbi.nlm.nih.gov/pubmed/25569128
http://dx.doi.org/10.1136/bmj.g7635
work_keys_str_mv AT hyttelsorensensimon cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT pelliceradelina cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT alderliestenthomas cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT austintopun cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT vanbelfrank cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT bendersmanon cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT clarisolivier cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT dempseyeugene cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT franzaxelr cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT fumagallimonica cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT gluudchristian cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT grevstadberit cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT hagmanncornelia cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT lemmerspetra cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT vanoeverenwim cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT pichlergerhard cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT plomgaardannemette cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT rierajoan cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT sanchezlaura cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT winkelper cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT wolfmartin cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial
AT greisengorm cerebralnearinfraredspectroscopyoximetryinextremelypreterminfantsphaseiirandomisedclinicaltrial